Effect of the ADRB1 1165C>G and 145A>G polymorphisms on hemodynamic response during dobutamine stress...

Area of Science:

• Cardiovascular Genetics
• Pharmacogenomics
• Clinical Echocardiography

Background:

• The ADRB1 gene encodes the beta-1 adrenergic receptor, a key regulator of cardiac function.
• Genetic variations in ADRB1 may influence individual responses to cardiovascular medications and stress tests.
• Dobutamine stress echocardiography (DSE) is a standard diagnostic tool for assessing cardiac function under stress.

Purpose of the Study:

• To investigate the association between ADRB1 1165C>G and 145A>G polymorphisms and hemodynamic responses during DSE.
• To determine if these specific ADRB1 gene variants affect heart rate (HR) and blood pressure (BP) changes in response to dobutamine.
• To analyze the impact of these polymorphisms on patients requiring atropine during DSE.

Main Methods:

• Genotyping of ADRB1 1165C>G and 145A>G polymorphisms using PCR-restriction fragment length polymorphism.
• Inclusion of 144 patients with clinical indications for DSE.
• Monitoring of hemodynamic parameters (HR, systolic BP, diastolic BP) throughout the DSE procedure.

Main Results:

• No significant differences in HR, systolic BP, or diastolic BP were observed between different genotypes of ADRB1 1165C>G and 145A>G.
• The magnitude of hemodynamic response (e.g., change in HR) to dobutamine was comparable across all analyzed genotypes.
• These findings held true even for the subgroup of patients who required atropine during DSE.

Conclusions:

• The studied ADRB1 1165C>G and 145A>G polymorphisms are not associated with hemodynamic responses to dobutamine.
• These genetic variations do not appear to influence HR, SBP, or DBP changes during diagnostic DSE in the studied Polish Caucasian population.
• The results suggest that routine genotyping for these specific ADRB1 polymorphisms may not be necessary for predicting DSE outcomes.